As previously reported, BofA analyst Travis Steed upgraded Inspire Medical (INSP) to Buy from Neutral with a price target of $255, up from $220. Inspire has turned the corner on profitability and margin upside seems durable, the analyst tells investors. The company is “now squarely in the profitable growth category” after two quarters of positive operating margin and is buying back stock, which is a “bullish sign” for margins and the free cash flow outlook, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical upgraded to Buy from Neutral at BofA
- Inspire Medical authorizes $75M accelerated share repurchase program
- Inspire Medical price target raised to $260 from $255 at Piper Sandler
- Inspire Medical price target raised to $252 from $240 at Baird
- Inspire Medical price target raised to $198 from $187 at Wells Fargo